These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 23804078)

  • 21. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
    Hardaway JC; Prince E; Arepally A; Katz SC
    J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
    [No Abstract]   [Full Text] [Related]  

  • 25. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
    Ozawa K
    Nihon Rinsho; 2014 Mar; 72(3):547-52. PubMed ID: 24724418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
    Torikai H; Cooper LJ
    Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
    Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
    Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 32. Chimeric antigen receptor-redirected T cells return to the bench.
    Geldres C; Savoldo B; Dotti G
    Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
    Eshhar Z
    Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?
    Hombach AA; Abken H
    Expert Rev Clin Immunol; 2017 Feb; 13(2):151-155. PubMed ID: 27546707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z
    Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
    Orlowski RJ; Porter DL; Frey NV
    Br J Haematol; 2017 Apr; 177(1):13-26. PubMed ID: 27977050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.